Threshold Pharmaceuticals Making Good Clinical Progress on Several Fronts

by M.E. Garza, Benzinga Contributor

December 14, 2011 10:12 AM | 4 min read | Make a Comment

Threshold Pharmaceuticals, Inc. THLD today announced clinical trial results of the Phase 1 study of TH-302 in patients with advanced leukemias conducted at MD Anderson's Cancer Center in Houston, Texas.

Market News and Data brought to you by Benzinga APIs

Posted In: Markets

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!